Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Stocks opened higher Thursday boosted by higher-than-expected earnings from Salesforce and as Wall Street looks to extend a late-summer winning streak.
